Rituximab (Rituxan), a blood cancer drug from Genentech, Inc and Biogen Idec has been denied approval for treating patients with rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including methotrexate (MTX).